OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2016.11.252
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Elsevier BV